The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global dry eye syndrome market size reached US$ 4.2 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 6 Billion by 2027, exhibiting at a CAGR of 5.95% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Dry eye syndrome, medically known as keratoconjunctivitis sicca (KCS), is a term that defines the lack of lubrication or moisture on the surface of the infected person’s eyes. It is a commonly occurring disease which can affect almost anyone. Various symptoms of dry eye include aching and burning sensations, sore eyes, red eyes, fatigued eyes, itchy eyes, photophobia, etc. Apart from this, watery eyes can also be a symptom as the dry surface of the eyes over-stimulate the production of watery component of tears in order to reduce the dryness. There are several factors that can cause dry eye syndrome such as excessive computer uses, allergies, aging, menopause, smoking, LASIK eye surgery, hormone replacement therapy, etc.
Various diseases, such as diabetes, thyroid disorders, Sjogren’s syndrome, lupus, scleroderma, rheumatoid arthritis, etc., are also contributing to the prevalence of dry eyes among people. As per statistics, around 425-430 Million individuals across the globe get affected by diabetes. It causes constant changes in the composition of patient’s blood which adversely affects the tear glands resulting in a rising prevalence of dry eye. Another key factor which is contributing to the growth of the market is the rising geriatric population. As per estimates, around 9% of the global population is above 65 years of age, and by 2050 this segment is expected to account for around 17% of the global population. With the prevalence of dry eyes being high among the elderly, we expect the market for dry eye syndrome to exhibit a strong growth. Other factors augmenting the growth of this market include increasing awareness levels, rising diagnostic rates, better treatment options, etc.
IMARC Group provides an analysis of the key trends in each sub-segment of the global dry eye syndrome market, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on disease type, drug type, product and distribution channel.
Breakup by Disease Type:
Based on the disease type, evaporative dry eye syndrome currently accounts for the highest market share.
Breakup by Drug Type:
Based on the drug type, anti-inflammatory drugs currently account for the highest market share.
Breakup by Product:
Based on the product type, liquid eye drops currently account for the highest market share.
Breakup by Distribution Channel:
Based on the distribution channel, hospital pharmacies currently account for the highest market share.
Breakup by Region:
On the geographical front, North America currently represents the biggest market for dry eye syndrome.
The competitive landscape of the market has also been examined with some of the key players being, Akorn Inc., Alimera Science, Allergan plc., Auven Therapeutics, Bausch + Lomb, GlaxoSmithKline plc, Nicox S.A., Novartis AG, Otsuka Holdings Co. Ltd. and Santen Pharmaceutical Co. Ltd.
|Base Year of the Analysis||2021|
|Segment Coverage||Disease Type, Drug Type, Product, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Companies Covered||Akorn Inc., Alimera Science, Allergan plc., Auven Therapeutics, Bausch + Lomb, GlaxoSmithKline plc, Nicox S.A., Novartis AG, Otsuka Holdings Co. Ltd. and Santen Pharmaceutical Co. Ltd.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License $ 2499
Five User License $ 3499
Corporate License $ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
The global dry eye syndrome market was valued at US$ 4.2 Billion in 2021.
We expect the global dry eye syndrome market to exhibit a CAGR of 5.95% during 2022-2027.
Increasing prevalence of dry eye syndrome as a common symptom for numerous medical ailments, such as Sjogren’s syndrome, lupus, scleroderma, rheumatoid arthritis, etc., represents one of the key factors driving the global dry eye syndrome market.
Sudden outbreak of the COVID-19 pandemic had led to a severe decline in hospital or clinic visits for mitigating the risk of coronavirus infection, thereby negatively impacting the demand for dry eye syndrome diagnosis and treatment procedures.
Based on the disease type, the global dry eye syndrome market has been divided into evaporative dry eye syndrome and aqueous dry eye syndrome, where evaporative dry eye syndrome currently holds the majority of the total market share.
Based on the drug type, the global dry eye syndrome market can be segregated into lubricant eye drops, anti-inflammatory drugs, and autologous serum eye drops. Among these, anti-inflammatory drugs exhibit the clear dominance in the market.
Based on the product, the global dry eye syndrome market has been bifurcated into liquid drops, gel, liquid wipes, eye ointment, and others. Currently, liquid eye drops represent the majority of the total market share.
Based on the distribution channel, the global dry eye syndrome market can be categorized into retail pharmacies, hospital pharmacies, and online pharmacies. Among these, hospital pharmacies currently account for the largest market share.
On a regional level, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America currently dominates the global market.
Some of the major players in the global dry eye syndrome market include Akorn Inc., Alimera Science, Allergan plc., Auven Therapeutics, Bausch + Lomb, GlaxoSmithKline plc, Nicox S.A., Novartis AG, Otsuka Holdings Co. Ltd., and Santen Pharmaceutical Co. Ltd.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at